Cofounders of a microbiome biobank speak with The Scientist about their new partnership with nonprofit OpenBiome and how to ethically work with donors.
Researchers overseeing the clinical trial for the first FDA-approved oral contraceptive claimed the drug gave the Puerto Rican participants power over their family planning. Critics claimed the women were exploited.
Ancient stashes of animal bones, tools, and other artifacts are often dismissed as archaic garbage heaps, but the deposits provide glimpses of the cultural practices and environmental conditions of past Indigenous settlements.
As a former committee member who now advises PETA, I believe that claims that the identities of committee members must be kept secret to protect their safety are unfounded.
Hundreds of the school’s faculty, students, and trainees are protesting its consideration of David Sabatini, who left his previous posts after alleged sexual misconduct.
The field of ancient DNA, which combines archaeology and anthropology with cutting-edge genetics, is requiring scientists to have frank conversations about when research is justified and who it benefits.
Attorneys for the family seek compensation for the company’s sale of cells cloned from tissue removed without consent by doctors at Johns Hopkins Hospital 70 years ago.
The guidance comes after two years of consulting with hundreds of stakeholders, including indigenous peoples, religious leaders, patient groups, and scientists.
Removal of the 14-day limit for culturing human embryos is one of the main changes in the revised recommendations from the International Society for Stem Cell Research.
After resigning from the University of New England last year, Geoffrey Bove continues to study the effects of massage on rats in a facility he set up in his house.
A new ruling removes the requirement that grants and proposals using the material receive approval from an ethical review board, reverting to the process in place before 2019.
